keyword
MENU ▼
Read by QxMD icon Read
search

Pet psma

keyword
https://www.readbyqxmd.com/read/29045711/the-endothelial-prostate-specific-membrane-antigen-is-highly-expressed-in-gliosarcoma-and-visualized-by-68ga-psma-11-pet-a-theranostic-outlook-for-brain-tumor-patients
#1
Marcus Unterrainer, Maximilian Niyazi, Viktoria Ruf, Peter Bartenstein, Nathalie L Albert
No abstract text is available yet for this article.
October 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29044297/psa-levels-psa-doubling-time-gleason-score-and-prior-therapy-cannot-predict-measured-uptake-of-68-ga-psma-hbed-cc-lesion-uptake-in-recurrent-metastatic-prostate-cancer
#2
Frederik A Verburg, David Pfister, Natascha I Drude, Felix M Mottaghy, Florian Behrendt
AIM: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict the degree of tracer uptake on [(68)Ga]PSMA-HBED-CC PET/CT. MATERIALS & METHODS: We retrospectively studied 124 patients with recurrent an/or metastatic PCA who underwent [(68)Ga]PSMA-HBED-CC PET/CT. The maximum standardized uptake value (SUVmax) was determined in the prostate bed as well as in three size categories (≤ 5 mm, > 5-15 mm, > 15 mm) in pelvic lymph node, extrapelvic lymph node, bone and visceral metastases...
October 18, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/29038888/simultaneous-whole-body-18-f-psma-1007-pet-mri-with-integrated-high-resolution-multiparametric-imaging-of-the-prostatic-fossa-for-comprehensive-oncological-staging-of-patients-with-prostate-cancer-a-pilot-study
#3
Martin T Freitag, Claudia Kesch, Jens Cardinale, Paul Flechsig, Ralf Floca, Matthias Eiber, David Bonekamp, Jan P Radtke, Clemens Kratochwil, Klaus Kopka, Markus Hohenfellner, Albrecht Stenzinger, Heinz-Peter Schlemmer, Uwe Haberkorn, Frederik Giesel
INTRODUCTION: The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body (18)F-PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients. METHODS: Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after (18)F-PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence...
October 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29037965/prostate-cancer-specific-pet-radiotracers-a-review-on-the-clinical-utility-in-recurrent-disease
#4
Jaden D Evans, Krishan R Jethwa, Piet Ost, Scott Williams, Eugene D Kwon, Val J Lowe, Brian J Davis
Prostate cancer-specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine. Review of the literature generally favors PSMA-based agents for the detection of recurrence as a function of low PSA levels...
July 20, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29036003/68ga-prostate-specific-membrane-antigen-avid-tubercular-lesions-mimicking-prostate-cancer-metastasis-on-simultaneous-prostate-specific-membrane-antigen-pet-mri
#5
Aashim Ahuja, Sangeeta Taneja, Kiran Thorat, Amarnath Jena
Ga-prostate-specific membrane antigen (PSMA) has gained increasing interest as a target molecule in imaging of prostate cancer because of its selective overexpression in local prostate cancer lesions and metastasis. We report a case of a 62-year-old man with raised serum prostate-specific antigen levels who presented for Ga-PSMA HBED-CC simultaneous PET/MRI for prostate cancer evaluation. A PSMA-nonavid PI-RADS 5 (Prostate Imaging-Reporting and Data System) lesion was confirmed as adenocarcinoma on histopathology...
October 13, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29034176/imaging-tumour-thrombus-of-clear-cell-renal-cell-carcinoma-fdg-pet-or-psma-pet-direct-in%C3%A2-vivo-comparison-of-two-technologies
#6
Seyedehpariya Saadat, Bibiana Tie, Simon Wood, Ian Vela, Handoo Rhee
No abstract text is available yet for this article.
January 2018: Urology Case Reports
https://www.readbyqxmd.com/read/29032394/clinical-performance-of-68-ga-psma-11-pet-mri-for-the-detection-of-recurrent-prostate-cancer-following-radical-prostatectomy
#7
Benedikt Kranzbühler, Hannes Nagel, Anton S Becker, Julian Müller, Martin Huellner, Paul Stolzmann, Urs Muehlematter, Matthias Guckenberger, Philipp A Kaufmann, Daniel Eberli, Irene A Burger
PURPOSE: Sensitive visualization of recurrent prostate cancer foci is a challenge in patients with early biochemical recurrence (EBR). The recently established (68)Ga-PSMA-11 PET/CT has significantly improved the detection rate with published values of up to 55% for patients with a serum PSA concentration between 0.2-0.5 ng/mL. The increased soft tissue contrast in the pelvis using simultaneous (68)Ga-PSMA-11 PET/MRI might further improve the detection rate in patients with EBR and low PSA values over PET/CT...
October 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29029496/-177-lu-psma-617-radioligand-therapy-for-a-patient-with-lymph-node-metastatic-prostate-cancer
#8
Finn E von Eyben, Timo Kiljunen, Timo Joensuu, Kalevi Kairemo, Christian Uprimny, Irene Virgolini
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. (177)Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report describes a patient with a third recurrence in lymph nodes. The recurrence was treated with (177)Lu-PSMA radioligand therapy instead of chemotherapy with docetaxel. The effect was in part evaluated relative to that of two established salvage treatments...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29028767/prostate-specific-membrane-antigen-guided-salvage-lymph-node-dissection-in-recurrent-prostate-cancer-a-novel-technology-to-detect-lymph-node-metastases
#9
Tobias Maurer, Jürgen E Gschwend, Matthias Eiber
PURPOSE OF REVIEW: With Gallium (Ga)-prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) as emerging imaging technique offering superior detection rates in biochemical recurrent prostate cancer, salvage lymph node dissection has gained increasing interest in localized oligometastatic prostate cancer. Currently, PSMA-targeting small molecules cannot only be linked to positron-emitting isotopes for imaging but also be labelled with γ-radiation emitting isotopes. These modified PSMA agents are evaluated for intraoperative guidance for resection of metastatic lymph nodes...
October 11, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29022058/-psma-radioguided-surgery-in-localised-recurrent-prostate-cancer
#10
REVIEW
T Horn, I Rauscher, M Eiber, J E Gschwend, T Maurer
Recently, prostate-specific membrane antigen radioguided surgery (PSMA-RGS) was introduced for targeted resection of localised prostate cancer recurrence. Preliminary results show that PSMA-RGS is very sensitive and specific in tracking suspicious lesions intraoperatively. Prerequisite for PSMA-RGS is a positive (68)Ga-PSMA positron emission tomography (PET) scan with a preferably singular soft tissue or lymph node recurrence. The first 63 patients treated with PSMA-RGS were analyzed. The extracorporal analysis of a total of 277 tissue specimens yielded the following test quality criteria regarding the presence of malignant tissue: sensitivity 86...
October 11, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28986512/cold-kit-psma-pet-imaging-phase-i-study-of-68-ga-thp-psma-pet-ct-in-patients-with-prostate-cancer
#11
Michael S Hofman, Peter Eu, Price Jackson, Emily Hong, David Binns, Amir Iravani, Declan Murphy, Catherine Mitchell, Shankar Siva, Rodney J Hicks, Jennifer D Young, Philip Blower, Gregory E Mullen
Objectives: Ga-68 labelled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as (68)Ga-HBED-PSMA-11, are promising small molecules for targeting prostate cancer. A new radiopharmaceutical (68)Ga-THP-PSMA has a simplified design for one-step kit-based radiolabelling. It features the tris(hydroxypyridinone) (THP) ligand, which complexes (68)Ga3+ rapidly at low concentration, room temperature and over a wide pH range, enabling direct elution from a (68)Ge/(68)Ga generator into a lyophilized kit in one-step without manipulation...
October 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28986509/why-targeting-psma-is-a-game-changer-in-the-management-of-prostate-cancer-%C3%A2-a-urologist-s-point-of-view
#12
Nicholas M Donin, Robert Reiter
Prostate-specific membrane antigen (PSMA), is a transmembrane glycoprotein that is highly expressed on prostate adenocarcinomas, exhibits only limited expression in benign and extra-prostatic tissues, and thus represents an ideal target for the diagnosis and management of prostate cancer. Since its discovery over 30 years ago, significant effort has been made to develop clinical technology targeting PSMA. The last 5 years have seen an explosion of development of new agents targeting PSMA for diagnostic and therapeutic use...
October 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28980045/-the-role-of-psma-pet-ct-in-patients-with-metastatic-prostate-cancer
#13
REVIEW
J von Hardenberg, K-A Büsing, P Nuhn, M Ritter
Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy...
October 4, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28964633/synthesis-and-evaluation-of-a-novel-near-infrared-fluorescent-probe-based-on-succinimidyl-cys-c-o-glu-that-targets-prostate-specific-membrane-antigen-for-optical-imaging
#14
Daiko Matsuoka, Hiroyuki Watanabe, Yoichi Shimizu, Hiroyuki Kimura, Masahiro Ono, Hideo Saji
Prostate-specific membrane antigen (PSMA), which is highly expressed in both localized and metastatic prostate cancer (PCa), is an ideal target for imaging and therapy of PCa. We previously reported radiolabeled asymmetric urea derivatives asa PSMA-targeting radiotracer for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging. Here, based on these radiopharmaceutical probes, we designed a novel near-infrared (NIR) fluorescent imaging probe (800CW-SCE) by chemical conjugation between IRDye 800CW-Maleimide and an asymmetric urea compound, known as PSMA inhibitor, for optical imaging...
September 18, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28957842/comparison-of-68ga-psma-pet-ct-and-multiparametric-mri-for-staging-of-high-risk-prostate-cancer68ga-psma-pet-and-mri-in-prostate-cancer
#15
Shruti Tulsyan, Chandan J Das, Madhavi Tripathi, Amlesh Seth, Rajeev Kumar, Chandrasekhar Bal
INTRODUCTION: We carried out this study to compare Glu-NH-CO-NH-Lys-(Ahx) [Ga(HBED-CC)] [Ga prostate-specific membrane antigen-11 (PSMA-11)] PET with multiparametric MRI (mpMRI) for the staging of high-risk prostate cancer. PATIENTS AND METHODS: This was a prospective study in which 36 patients with high-risk prostate cancer were included. The criteria for inclusion were biopsy-proven prostate cancer with a serum prostate specific antigen of at least 20 and/or Gleason's score of at least 8...
September 27, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28953234/procedures-for-the-gmp-compliant-production-and-quality-control-of-18-f-psma-1007-a-next-generation-radiofluorinated-tracer-for-the-detection-of-prostate-cancer
#16
Jens Cardinale, René Martin, Yvonne Remde, Martin Schäfer, Antje Hienzsch, Sandra Hübner, Anna-Maria Zerges, Heike Marx, Ronny Hesse, Klaus Weber, Rene Smits, Alexander Hoepping, Marco Müller, Oliver C Neels, Klaus Kopka
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer. In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [(18)F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [(18)F]DCFPyL and [(18)F]DCFBC. Since radiosynthesis so far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses of [(18)F]PSMA-1007 have been developed...
September 27, 2017: Pharmaceuticals
https://www.readbyqxmd.com/read/28950199/validation-of-a-al-18-f-psma-11-preparation-for-clinical-applications
#17
Ehab Al-Momani, Ina Israel, Samuel Samnick
Imaging prostate-specific membrane antigen (PSMA) using positron emission tomography (PET) has been presented so far as the most sensitive and specific with regard to prostate cancer detection, in particular in high-risk prostate cancer patients. Currently, it mainly features Gallium-68 ((68)Ga) labeled PSMA ligands, notably [(68)Ga]Glu-urea-Lys(Ahx)-HBED-CC ([(68)Ga]-PSMA-11) and [(68)Ga]DOTAGA-FFK (Sub-KuE termed ([(68)Ga]PSMA-I&T). However, (68)Ga has several shortcomings as radionuclide including a short half-life and non-ideal energies...
September 6, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28941866/-68-ga-psma-pet-ct-in-prostate-cancer
#18
J R García Garzón, M de Arcocha Torres, R Delgado-Bolton, F Ceci, S Alvarez Ruiz, J Orcajo Rincón, A P Caresia Aróztegui, M J García Velloso, A M García Vicente
Positron emission tomography/computed tomography (PET/CT) with (68)Ga-PSMA is a non-invasive diagnostic technique to image prostate cancer with increased prostate-specific membrane antigen (PSMA) expression. PSMA is a transmembrane protein present in all prostatic tissues. Increased PSMA expression is seen in several malignancies, although prostate cancer is the tumour where it presents higher concentrations. Almost all prostate adenocarcinomas show PSMA expression in most of lesions, primary and metastatic...
September 20, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28929350/optimal-mri-sequences-for-68-ga-psma-11-pet-mri-in-evaluation-of-biochemically-recurrent-prostate-cancer
#19
Spencer T Lake, Kirsten L Greene, Antonio C Westphalen, Spencer C Behr, Ronald Zagoria, Eric J Small, Peter R Carroll, Thomas A Hope
BACKGROUND: PET/MRI can be used for the detection of disease in biochemical recurrence (BCR) patients imaged with (68)Ga-PSMA-11 PET. This study was designed to determine the optimal MRI sequences to localize positive findings on (68)Ga-PSMA-11 PET of patients with BCR after definitive therapy. Fifty-five consecutive prostate cancer patients with BCR imaged with (68)Ga-PSMA-11 3.0T PET/MRI were retrospectively analyzed. Mean PSA was 7.9 ± 12.9 ng/ml, and mean PSA doubling time was 7...
September 19, 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28924629/a-psma-ligand-labeled-with-cobalt-55-for-pet-imaging-of-prostate-cancer
#20
Johan Hygum Dam, Birgitte Brinkmann Olsen, Christina Baun, Poul Flemming Høilund-Carlsen, Helge Thisgaard
PURPOSE: Prostate-specific membrane antigen (PSMA) comprises a recognized target for molecular imaging of prostate cancer. As such, radiolabeled PSMA inhibitors are of great value for diagnosis and staging of this disease. Herein, we disclose the preclinical characterization of [(55)Co]PSMA-617 for positron emission tomography (PET)/x-ray computed tomography (CT) imaging of prostate cancer lesions. PROCEDURES: By the application of microwave heating, PSMA-617 in acetate buffer (0...
September 18, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
keyword
keyword
110902
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"